Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Cancer Survivors Found to Be at Greater Risk of Frailty-Related Bone Fractures

November 18, 2022
By Nicholas Wrigley
Article

Factors such as chemotherapy treatment and a cancer diagnosis within the past 5 years were associated with a greater risk of frailty-related bone fractures among older cancer survivors, according to findings from a recent cohort study.

Cancer survivors have a significantly higher risk of frailty-related bone fractures for several years after diagnosis vs those without a history of cancer, according to findings from a recent study published in JAMA Oncology.

Older adults with a history of cancer were found to have a 57% greater risk of fractures in the first year after diagnosis (HR 1.57; 95% CI, 1.38-1.79) vs those without. The risk was especially elevated for those diagnosed with distant metastases 1 to 4 years prior to the study (HR 2.12; 95% CI, 1.75-2.58). This disparity in risk derived largely from vertebral (HR 2.46; 95% CI, 1.93-3.13) and pelvic (HR, 2.46; 95% CI 1.84-3.29) fractures. The risk of radial fracture meanwhile did not substantially vary based on history of cancer (HR 1.09; 95% CI, 0.64-1.87).

“Cancer survivors are at higher risk of bone fractures likely because of higher rates of osteoporosis coupled with low muscle mass, poor balance, and unexpected changes in gait,” the investigators wrote. “One novel finding in this study was the difference in risk by fracture site….[It] is important to understand the differences in risk by fracture site because each fracture type is associated with certain health care costs and risks of subsequent morbidity and mortality. Pelvic fractures, in particular, are highly associated with further health issues, including mortality, and account for nearly 77% of all costs incurred from incident fractures.”

Other relevant risk factors included treatment modality, lifestyle, and sex. Survivors of cancer who received chemotherapy were 31% more likely to have a fracture vs those who didn’t receive chemotherapy (HR 1.31; 95% CI, 1.09-1.57) in the first 4 years after diagnosis and 22% more likely 5 or more years beyond diagnosis (HR 1.22; 95% CI, 0.99-1.51). Additionally, survivors who were current smokers at the time of the study were more than twice as likely to have fractures (HR 2.27; 95% CI, 1.55-3.33) as those who never smoked. The risk of fracture was lower among physically active survivors 5 or more years after diagnosis (HR 0.76; 95% CI, 0.54-1.07), but this correlation was not statistically significant. Higher BMI (≥25) was also associated with lower risk of fracture for those with (HR 0.72; 95% CI, 0.62-0.85) and without (HR 0.78; 95% CI, 0.75-0.81) a history of cancer. Men were generally less likely to experience fractures than women, including in those without a history of cancer (HR 0.51; 95% CI, 0.48-0.54), in survivors 1 to 4 years after diagnosis (HR 0.53; 95% CI, 0.41-0.69), and in survivors 5 or more years beyond (HR, 0.74; 95% CI, 0.54-1.01), though the latter correlation was not statistically significant.

This longitudinal cohort study examined 92,413 eligible participants out of 116,355 adults who completed the 1999 Cancer Prevention Study II Nutrition Cohort survey and were linked with Medicare claims from 1999 to 2017. The vast majority of this study population were White (97.9%) and older than 60 years (95.8%) at the time of the survey. The median age was 69.4 years, and most participants were women (56%). Most either met (24.1%) or significantly exceeded (32.3%) the guidelines for moderate to vigorous physical activity, and most (54.2%) had a BMI of 25 or greater. Current smokers comprised 4.7% of the population, with former smokers comprising a further 48.6%.

Incident fractures affected 12,943 participants in total. The primary analysis only included first fractures because roughly 4% (n = 3793) of participants experienced more than one; further exploratory analyses assessed the risks related to multiple fractures.

“Future studies are needed that explore the associations of [moderate- to vigorous-intensity physical activity], strength training, smoking, alcohol use, or diet quality across the life course, both before and after diagnosis, with fracture risk in [survivors of cancer],” the investigators concluded, writing nonetheless that “[these] survivors, especially those who received chemotherapy or received a cancer diagnosis more recently (<5 years), may benefit from clinical guidance on frailty-related fracture prevention.”

Reference

Rees-Punia E, Newton CC, Parsons HM, et al. Fracture risk among older cancer survivors compared with older adults without a history of cancer. JAMA Oncol. Published online November 3, 2022. doi:10.1001/jamaoncol.2022.5153

Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Related Content
Advertisement

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Ariana Pelosci
August 25th 2025
Article

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.


The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 14th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

Related Content
Advertisement

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment

Ariana Pelosci
August 25th 2025
Article

The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 25th 2025
Podcast

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.


The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.


Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 14th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.